Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date

Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January